164 related articles for article (PubMed ID: 38665375)
1. Ustekinumab in pediatric patients with Crohn's disease: safety, and efficacy results from a multicenter retrospective study in China.
Li P; Wang L; Tang Z; Wang Y; Liu Z; Ge W; Huang Y
Front Pediatr; 2024; 12():1371322. PubMed ID: 38665375
[TBL] [Abstract][Full Text] [Related]
2. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
[TBL] [Abstract][Full Text] [Related]
3. Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.
Yerushalmy-Feler A; Pujol-Muncunill G; Martin-de-Carpi J; Kolho KL; Levine A; Olbjørn C; Granot M; Bramuzzo M; Rolandsdotter H; Mouratidou N; Hradsky O; Scarallo L; Matar M; Rimon RM; Rinawi F; Shalem T; Najajra H; de Meij T; Aloi M; Rodríguez-Belvís MV; Alvisi P; Schneider AM; van Rheenen P; Navas-López VM; Kiparissi F; Barrio J; Turner D; Cohen S
J Pediatr Gastroenterol Nutr; 2022 Dec; 75(6):717-723. PubMed ID: 36084231
[TBL] [Abstract][Full Text] [Related]
4. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response.
Heron V; Li Fraine S; Panaccione N; Restellini S; Germain P; Candido K; Bernstein CN; Bessissow T; Bitton A; Chauhan UK; Lakatos PL; Marshall JK; Michetti P; Seow CH; Rosenfeld G; Panaccione R; Afif W
J Can Assoc Gastroenterol; 2022 Oct; 5(5):208-213. PubMed ID: 36196277
[TBL] [Abstract][Full Text] [Related]
6. P066 Real-World Experience of Ustekinumab in Crohn's Disease Patients With Prior Anti-TNF Therapy at a Tertiary Care Hospital.
Tripathi K; Groudan K; Chalhoub J; Yedla A; Singhania R
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S17. PubMed ID: 37461983
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Danese S; Panaccione R; Feagan BG; Afzali A; Rubin DT; Sands BE; Reinisch W; Panés J; Sahoo A; Terry NA; Chan D; Han C; Frustaci ME; Yang Z; Sandborn WJ; Hisamatsu T; Andrews JM; D'Haens GR;
Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):133-146. PubMed ID: 38104569
[TBL] [Abstract][Full Text] [Related]
8. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Danese S; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravata I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Peyrin-Biroulet L;
Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):294-306. PubMed ID: 35120656
[TBL] [Abstract][Full Text] [Related]
9. Multimodal dynamic ultrasound approach as predictor of response in patients with Crohn's disease treated with ustekinumab.
Ainora ME; Liguori A; Mignini I; Cintoni M; Galasso L; Laterza L; Lopetuso LR; Garcovich M; Riccardi L; Gasbarrini A; Scaldaferri F; Zocco MA
Therap Adv Gastroenterol; 2024; 17():17562848241259289. PubMed ID: 38912296
[TBL] [Abstract][Full Text] [Related]
10. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
11. [Clinical remission and transmural healing of ustekinumab in patients with Crohn's disease].
Wu Y; Xu Y; Zhang G; Zhang Y; Wang J; You P; Peng T; Liu Y; Chen N
Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 56(2):253-259. PubMed ID: 38595241
[TBL] [Abstract][Full Text] [Related]
12. Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study.
Chavannes M; Martinez-Vinson C; Hart L; Kaniki N; Chao CY; Lawrence S; Jacobson K; Hugot JP; Viala J; Deslandres C; Jantchou P; Seidman EG
J Crohns Colitis; 2019 Apr; 13(5):578-584. PubMed ID: 30541021
[TBL] [Abstract][Full Text] [Related]
13. [Analysis on the efficacy of dual vein induction therapy of Ustekinumab in complex perianal fistulizing Crohn's disease].
Zhang DL; Shao XX; Hu DY; Lin DP; Wu H; Jiang Y
Zhonghua Yi Xue Za Zhi; 2023 Nov; 103(41):3301-3306. PubMed ID: 37926575
[No Abstract] [Full Text] [Related]
14. Experience Using Ustekinumab in Pediatric Patients With Medically Refractory Crohn Disease.
Kim FS; Patel PV; Stekol E; Ali S; Hamandi H; Heyman MB; Verstraete SG
J Pediatr Gastroenterol Nutr; 2021 Nov; 73(5):610-614. PubMed ID: 34415711
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn's disease: a KASID prospective multicenter study.
Oh K; Hong HS; Ham NS; Lee J; Park SH; Yang SK; Yoon H; Kim YS; Choi CH; Ye BD;
Intest Res; 2023 Jan; 21(1):137-147. PubMed ID: 36751044
[TBL] [Abstract][Full Text] [Related]
16. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T
Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512
[No Abstract] [Full Text] [Related]
17. Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.
Straatmijer T; Biemans VBC; Moes DJAR; Hoentjen F; Ter Heine R; Maljaars PWJ; Theeuwen R; Pierik M; Duijvestein M; van der Meulen-de Jong AE;
Dig Dis Sci; 2023 Jun; 68(6):2647-2657. PubMed ID: 36920666
[TBL] [Abstract][Full Text] [Related]
18. Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn's disease: a real-world multicenter Brazilian study.
Parra RS; Chebli JMF; Queiroz NSF; Damião AOMC; de Azevedo MFC; Chebli LA; Bertges ER; Alves Junior AJT; Ambrogini Junior O; da Silva BLPS; Lubini M; Bafutto M; Flores C; Vilela EG; Boratto SF; Gasparetti Junior NLT; Steinwurz F; Carvalho NS; Féres O; da Rocha JJR
BMC Gastroenterol; 2022 Apr; 22(1):199. PubMed ID: 35448949
[TBL] [Abstract][Full Text] [Related]
19. Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children's hospital in Japan.
Takeuchi I; Arai K; Kyodo R; Sato T; Tokita K; Hirano Y; Shimizu H
J Gastroenterol Hepatol; 2021 Jan; 36(1):125-130. PubMed ID: 32497325
[TBL] [Abstract][Full Text] [Related]
20. Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing.
Argüelles-Arias F; Valdés Delgado T; Maldonado Pérez B; González Antuña J; Castro Laria L
Therap Adv Gastroenterol; 2023; 16():17562848231191670. PubMed ID: 37655058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
